Concord Repatriation General Hospital, commonly referred to as Concord Hospital, is a major hospital in Sydney, Australia, on Hospital Road in Concord.

There are 500 beds in Concord Repatriation General Hospital.

During the past decade, Concord Repatriation General Hospital conducted 115 clinical trials. In the 10-year time frame, 115 clinical trials started and 59 clinical trials were completed, i.e. on average, 51.3% percent of trials that started reached the finish line to date. In the past 5 years, 42 clinical trials started and 29 clinical trials were completed. i.e. 69% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Concord Repatriation General Hospital" #1 sponsor was "Celgene" with 15 trials, followed by "Pfizer" with 12 trials sponsored, "BeiGene" with 11 trials sponsored, "Gilead Sciences" with 10 trials sponsored and "Hoffmann-La Roche" with 10 trials sponsored. Other sponsors include 126 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Concord Repatriation General Hospital" #1 collaborator was "National Health and Medical Research Council, Australia" with 8 trials as a collaborator, "AbbVie" with 4 trials as a collaborator, "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 4 trials as a collaborator, "Bayer" with 4 trials as a collaborator and "Abbott Medical Devices" with 2 trials as a collaborator. Other collaborators include 140 different institutions and companies that were collaborators in the rest 131 trials.

According to Clinical.Site data, the most researched conditions in "Concord Repatriation General Hospital" are "Crohn's Disease" (13 trials), "Ulcerative Colitis" (13 trials), "Crohn Disease" (9 trials), "Colitis, Ulcerative" (5 trials) and "Idiopathic Pulmonary Fibrosis" (5 trials). Many other conditions were trialed in "Concord Repatriation General Hospital" in a lesser frequency.

Most popular intervention types in "Concord Repatriation General Hospital" are "Drug" (159 trials), "Other" (28 trials), "Biological" (16 trials), "Procedure" (9 trials) and "Device" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (57 trials), "Zanubrutinib" (7 trials), "Rituximab" (6 trials), "Etrolizumab" (4 trials) and "GED-0301" (4 trials). Other intervention names were less common.

The vast majority of trials in "Concord Repatriation General Hospital" are 178 trials for "All" genders, 6 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are 74 active trials in "Concord Repatriation General Hospital". 1 are not yet recruiting, 41 are recruiting, 30 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 89 completed trials in Concord Repatriation General Hospital, undefined suspended trials, and 21 terminated clinical trials to date.

Out of the total trials that were conducted in Concord Repatriation General Hospital, 14 "Phase 1" clinical trials were conducted, 42 "Phase 2" clinical trials and 110 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 14 trials that are defined as “Not Applicable".